finance.yahoo.com

FDA Approves Abbott Libre Duo 10-Day Wearable for Continuous Ketone Tracking

Abbott Laboratories logoAbbott Laboratories
Sig3.32Sen+4.44Env+0.03Soc+3.35Gov+0.86

The FDA granted Abbott marketing authorization via the De Novo pathway for the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The sensors continuously alert users when ketones rise, replacing single-point urine or blood testing, based on six clinical studies covering over 600 participants. Abbott is also working to link the sensors with automated insulin delivery pumps.

Coverage (2)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro